Stromal cells play an important role in the structural and functional properties of epithelium in many organs. In normal development of the genitourinary system, stromal cells play a critical role in directing epithelial differentiation. Cunha and colleagues demonstrated in experiments with rodents that the gender of origin of stromal mesenchyme cells determined the differentiation of juxtaposed, co-implanted epithelial cells. Specifically, male mesenchyme directed co-implanted female epithelium to form androgen receptor-expressing glands. Conversely, female mesenchyme directed co-implanted male epithelium to form estrogen receptor-expressing vaginal epithelium-like, stratified squamous epithelium.[@R1]

Extending these concepts to human prostate carcinoma, these investigators showed that prostate cancer-associated fibroblasts could induce proliferation and malignant transformation of cultured prostate epithelial cells under androgen stimulation, in contrast to non-cancer associated fibroblasts.[@R1] Furthermore, there is evidence that prostate cancer-associated stroma "drives" tumor progression, mediated by growth factors of stromal cells.[@R2] Similar dependence of proliferation and other cancer-associated properties on stromal cells has been shown in other tissues, such as the breast. However, little is known of the molecular details of these processes. Neither the molecular phenotype of prostate cancer-associated fibroblasts, nor the molecular mediators of the stromal/epithelial interaction have been characterized.

Identifying cell membrane molecules that characterize and distinguish different parenchymal cell types is of biological importance. These molecules are critical for a range of functional properties including cell signaling, receptor activation, and cell adhesion. These molecules can also be used as markers to identify and sort defined cell types, and to serve as cell-specific targets for therapy. Using monoclonal antibodies specific to the cell membrane CD (cluster designation) molecules, we have characterized the parenchymal cells of the prostate, and identified CD molecules that are uniquely expressed by the various parenchymal cells of the prostate.[@R3] Furthermore, we have found that primary prostate carcinomas that differ in their CD phenotype have apparently different malignant potential.[@R4] We now extend these studies to characterizing the phenotype of cancer-associated stroma with the goal of better understanding the molecular aspects of stroma/cancer cell interaction. One practical application is in determining whether the presence of these cancer-associated stromal cells could be used for cancer detection.

Materials and methods {#S1}
=====================

This study is approved by our Institutional Review Board.

Analysis of Differentially Expressed Proteins in Cancer {#S2}
-------------------------------------------------------

### Glycopeptide-capture proteomic analysis of tissue preparations {#S3}

Matched cancer and non-cancer tissue specimens were dissected from surgically resected glands. The tissue samples were minced and digested by collagenase in serum-free RPMI1640 media supplemented with 10^-8^ M dihydrotestosterone. The cell-free post-digestion supernatants of 2 pairs of cancer/non-cancer cases were used for identification of differentially expressed *N*-linked glycoproteins by glycopeptide-capture tandem mass spectrometry.[@R5]-[@R7] This method involved: a) glycoprotein oxidation with periodate to convert the *cis*-diol of carbohydrate to aldehyde; b) coupling of the generated aldehyde to hydrazide on solid support; c) proteolysis of immobilized glycoproteins by trypsin; d) isotopic labeling of cancer and non-cancer samples; e) release of labeled glycopeptides by peptide-*N*-glycosidase (PNGase) F; and f) analysis of peptides by μLC-ESI-MS/MS (microcapillary liquid chromatography-electrospray ionization-tandem mass spectrometry) or μLC followed by MALDI-MS/MS (matrix-assisted laser desorption/ionization tandem mass spectrometry). The proteins thus identified were predominantly classed as extracellular.[@R8] HPLC-grade reagents purchased from Fisher Scientific (Pittsburgh, PA) were used for chromatography procedures. PNGase F was purchased from New England Biolabs (Beverly, MA) and hydrazide resin from Bio-Rad (Hercules, CA). All other chemicals used in this study were purchased from Sigma (St. Louis, MO). Acquired MS/MS spectra were searched against the International Protein Index (IPI) human protein database (version 2.28, containing 40,110 entries) using [sequest]{.smallcaps} software.[@R9] The database search tool was set to include the following amino acids: carboxymethylated cysteines, oxidized methionines, and enzyme-catalyzed conversion of Asn to Asp at the site of carbohydrate attachment, and to accept at least 1 tryptic end and up to 2 missed cleavages. The mass tolerance for precursor ions was 3.0 Da and that for fragment ions was 0.6 Da. The default values were used for the other parameters in the database search. Search results were statistically analyzed using [PeptideProphet]{.smallcaps}, which effectively computes a probability (on a scale of 0 to 1) for the likelihood of each identification being correct in a data-dependent fashion.[@R10] A minimum [PeptideProphet]{.smallcaps} probability score filter of 0.9 was used to remove low probability peptides. Since *N*-linked glycosylation occurs at a consensus Asn-X-Ser/Thr sequon,[@R11] the remaining peptide sequences were additionally filtered to remove non-motif-containing peptides.

### Immunohistochemistry {#S4}

Primary prostate cancers from radical prostatectomy specimens comprised the tissue for the immunohistochemistry studies. Upon receipt of the radical prostatectomy specimen, 3-mm thick transverse sections were made after inking the exterior surface. Tissue blocks from the posterior aspect of each alternate transverse section were embedded in OCT (Optimal Cutting Temperature, Tissue-Tek, Torrance, CA) and snap frozen in isopentane that had been pre-cooled in liquid nitrogen. Frozen sections of these blocks provided a template for locating the cancer.

Frozen sections from ∼60 cases of OCT-embedded tissue were cut onto charged slides, fixed for 10 min in cold acetone and kept refrigerated at −20° until use. In staining with a monoclonal CD90 antibody (clone 5E10, BD-PharMingen, San Diego, CA), sections were incubated sequentially in solutions of 0.03% hydrogen peroxide, 0.5% albumin in phosphate-buffered saline (PBS), primary antibody (5 μg/ml), secondary biotinylated anti-mouse IgG (BA-2000, Vector Labs, Burlingame, CA) with interval washes in PBS. Reaction product was detected by incubating sections in solution of 0.05% diaminobenzidine (Invitrogen, Carlsbad, CA). The sections were counterstained with hematoxylin. Details of the method are available on the web (<http://scgap.systemsbiology.net/resources/protocols.php>).

### Western blot analysis {#S5}

Since the tissue-digestion media supernatants contained large amounts of added collagenase, amount used for analysis was based on g tissue/ml media instead of protein concentration. Samples were electrophoresed on 4-20% gradient SDS-polyacrylamide gels and electrotransferred to membrane. After treatment in 5% nonfat milk, the membrane was probed with CD90 antibody (1:500) for 60 min, followed by horseradish peroxidase conjugated anti-mouse IgG. Detection was by using Luminol (Santa Cruz Biotechnology, Santa Cruz, CA). Prostate-specific antigen (PSA) antibody (1:1,000, clone A67-B/E3, Santa Cruz Biotechnology) was used for sample loading control. Thirty cancer specimens were probed by Western and the result for 7 is shown in the data figure. Tissue inhibitor of metalloproteinase 1 (TIMP1) antibody (clone 7-6C1, Chemicon, Temecula, CA) was used at 1:1,000. TIMP1, a luminal secreted protein, is absent in cancer.[@R6]

Cancer-associated Stromal Cells {#S6}
-------------------------------

### Flow analysis of tumor tissue {#S7}

A tumor sample, 98-366, was dissected from the prostate with a stained section as guide. It was digested with collagenase in media with 10^-8^ M dihydrotestosterone. The resultant single cell suspension was analyzed for the percentage of CD57, CD107b, CD90 and CD49a cells by FACS as described.[@R12] CD57 and CD107b mark luminal epithelial cells; CD90 and CD49a mark stromal cells.[@R3]

### Laser-capture microdissection {#S8}

Five micron-thick sections were cut from OCT-embedded, frozen blocks of prostate tissue from 10 radical prostatectomy specimens. The sections were briefly stained (∼5 s) with RNase-free hematoxylin using HistoGene Staining Solution (Arcturus Engineering, Mountain View, CA), sequentially dehydrated through a gradient of ethanol into xylene, and allowed to air dry in low-humidity atmosphere for \<15 min. Using Arcturus Pixcell II laser-capture microscopy, approximately 2,000 stromal cells were obtained within 20 min from each section.[@R13] Both cancer-associated stromal cells (within 10 cell layers of cancer) and benign gland-associated stromal cells (within 10 cell layers of benign glands) were separately microdissected from each of these 10 blocks. Images of each laser-capture microdissection were taken for documentation.

### RNA amplification and gene expression analysis of stromal cells {#S9}

Captured cells were lysed in Arcturus RNA Extraction Buffer. RNA was isolated using Arcturus PicoPure RNA Isolation, and the samples were treated with RNase-Free DNase I Set (Qiagen, Valencia, CA). T7-based RNA amplification was carried out using MessageAmp Amplification (Ambion, Austin, TX). The first-round amplified RNA (aRNA) was used as a template for a second round of amplification to yield 50-150 μg aRNA.

Two μg aRNA was reverse transcribed using SuperScript II (Invitrogen). The reaction product was then hydrolyzed in 0.2 M NaOH, 0.1 M EDTA for 15 min at 65° and neutralized with 0.33 M Tris-HCl, pH 7.4. The cDNA was purified with Qiagen PCR clean-up column chromatography. Relative quantification of gene expression by PCR (40 cycles of 95°, 30 s; 60°, 30 s; 72°, 30 s) was done on 7700 Sequence Detector using SYBR Green Master (ABI, Foster City, CA) and gene-specific primers. Sample results were normalized to the cycle threshold value obtained in the exponential amplification of the housekeeping gene glyceraldehyde 3-phosphate dehydrogenase (GAPDH). Expression levels of CD90 were calculated, and values were reported as the ratio of gene expression in cancer-associated stromal cells to non-cancer tissue stromal cells. The error of the mean from 3 experiments was represented by error bars. Control reactions with RNA or water as template were negative. Amplification of a single PCR product per reaction was monitored by the generation of a single dissociation curve. The sequences of primers used were: GAPDH-5, CCTCAACGACCACTTTGTCA and GAPDH-3, TTACTCCTTGGAGGCCATGT; CD90-5, TCAGGAAATGGCTTTTCCCA and CD90-3, TCCTCAATGAGATGCCATAAGCT. The CD90 primers match to sequences 100 bp apart in the 3′ untranslated region (UTR) of the mRNA near the poly-A sequence.

Urine analysis {#S10}
--------------

### Proteomic analysis of urine {#S11}

Isotope coded affinity tag (ICAT) labeling and MS/MS was used to identify differentially expressed proteins in urine samples collected from consented pre-op(erative) and post-op patients. The urine samples were collected and stored overnight at 4° before use. Urinary proteins as assessed by silver staining of polyacrylamide gels were found to be stable for at least 1 week at that temperature (for long term, the samples were stored at −80°). Western blot analysis for the male-specific prostatic acid phosphatase (PAP/ACPP) showed a single discrete band (data not shown). Fifteen ml of urine were concentrated with spin filters (3-kDa cutoff) to yield protein concentrations ranging from 1.4 to 3.7 mg/ml. For ICAT labeling,[@R14],[@R15] 200-300 μg of concentrated proteins from each sample were used. After tryptic digestion, peptides were separated into 10 cation exchange fractions, and the labeled (isotope d0 or d9) Cys-containing peptides were isolated by avidin affinity chromatography. The peptides were analyzed by LC-MS/MS and the proteins were identified from the spectral data as described above. High abundance urinary proteins, as assessed by silver stained polyacrylamide gels, were identified by in-gel-digest followed by LC-MS/MS.[@R16]

In a different approach, urine samples were desalted and concentrated using Amicon Ultra-15 centrifugal filter MWCO3000 (Millipore, Billerica, MA). Protein concentration was determined by BCA Protein Assay (Thermo Scientific, Rockford, IL). An aliquot of concentrated protein sample was denatured in 50% trifluoroethanol at 60° for 2 h with gentle shaking, and then reduced with 2 mM DTT at 37° for 1 h. Samples were diluted 5-fold with 50 mM NH~4~HCO~3~ before digestion with trypsin (trypsin:protein 1:50 w/w) at 37° for 3 h. After speed-vac, peptides were reconstituted in 50 mM NH~4~HCO~3~ for LC-MS analysis. Urine peptide samples (0.5 μg/μl) were analyzed by capillary-LC-selected reaction monitoring (SRM)-MS on a TSQ Quantum Ultra triple quadrupole mass spectrometer (ThermoFisher Scientific, Waltham, MA) coupled with an in-house automated 4-column reverse phase HPLC system (Pacific Northwest National Laboratory). The mobile phase consisted of 0.1% formic acid in H~2~O (solution A) and 0.1% formic acid in acetonitrile (solution B). Five μl of peptides were loaded onto the column, and the mobile phase was maintained at 100% solution A for 20 min. The mobile phase was increased with solution B exponentially over 80 min to a final concentration of 70%. The reverse-phase capillary column was 75 *μ*m i.d. and 70 cm long fused silica (Polymicro Technologies, Phoenix, AZ) slurry-packed with 3 *μ*m C18 Jupiter bonded particles with 300 Å pores (Phenomenex, Torrence, CA). Q1 and Q3 resolution was set at 0.7 FWHM and Q2 collision gas pressure was 1.5 mTorr. Scan width and time were optimized as 0.001 *m/z* and 10 ms, respectively. Peptides for CD90 (and others) detected initially by LC-MS/MS of the same urine sample were selected for SRM analysis with the top 7 most abundant/intense fragments being monitored.

Results {#S12}
=======

Prostate tumor production of CD90 protein {#S13}
-----------------------------------------

The collagenase tissue digestion media preparations were used for proteomics on the assumption that during enzymatic treatment, cells remain metabolically active and continually secrete cell type-specific protein products. Previously, we have shown by Western blot analysis that there was minimal protein degradation, and the prostatic proteins of PSA/KLK3, ACPP and zinc-α2-glycoprotein (AZGP1) were readily detected.[@R6],[@R17] Our methodology specifically targeted *N*-linked glycoproteins, and identified a formerly *N*-glycopeptide, LDCRHE[NTS]{.ul}SSPIQYEFSLTR (mass 2541.15, *N*-glycosylation motif underlined), from CD90 with a quantitative increase in cancer. Another CD90 *N*-glycopeptide observed from the same glycosite was HE[NTS]{.ul}SSPIQYEFSLTR (1994.92, minus the *N*-terminal LDCR of the first). A different *N*-glycosite, DEGTYTCALHHSGHSPPISSQ[NVT]{.ul}VLR (2905.37), was also identified from CD90. [Table I](#T1){ref-type="table"} lists 10 proteins quantified in the 2 matched cancer and non-cancer specimens, and CD90 showed an increase of 5- and 4.5-fold respectively in the ratio of its signature peptide in cancer over non-cancer. The experimental data for CD90 is archived in <https://db.systemsbiology.net/sbeams/cgi/Glycopeptide/Glyco_prediction.cgi>. With the exception of CD90, most of the identified glycoproteins (e.g., PSA, [Table I](#T1){ref-type="table"}; TIMP1, not shown) in these collagenase digestion supernatants showed a decrease in cancer.

Western blot analysis confirmed the glycopeptide capture result. For each cancer specimen analyzed, there was an increased amount of CD90 protein (∼27 kDa) compared to non-cancer ([Fig. 1](#F1){ref-type="fig"}). As shown also, these specimens were low in TIMP1 (30 kDa), which is synthesized by luminal cells in non-cancer but not by cancer cells.[@R6] PSA was detected in both cancer and non-cancer specimens.[@R17] The increase in CD90 was found in different Gleason scores; in peripheral zone as well as transition zone cancers. A tumor specimen protein profile can thus be characterized as CD90^hi^TIMP1^lo^, and a non-cancer specimen as CD90^lo^TIMP1^hi^. The presumably GPI-anchored CD90 appeared to be released from the cells.

Immunohistochemical analysis of prostate cancer samples showed distinct and differential overexpression of CD90 in cancer-associated stroma compared with non-cancer tissue stroma. The increased CD90 protein level (based on the increased number of stained stromal cells, [Fig. 2](#F2){ref-type="fig"}) was seen in all 30 peripheral zone and transition zone tumors studied. No difference was observed in cancers of different Gleason grade. The image results for 43 radical prostatectomy specimens are available for query and download at <https://db.systemsbiology.net/sbeams/cgi/Immunostain/main.cgi?set_current_project_id=274> and <https://db.systemsbiology.net/sbeams/cgi/Immunostain/SummarizeStains>. The increased number of stained stromal cells, which did not extend beyond 10 stromal cells from the tumor cells, was localized around the cancer glands. For a typical benign gland, there was some CD90 staining just outside the basal epithelium, but it was weak elsewhere in the stroma. Flow analysis of a cancer specimen showed a high percentage of CD90^+^ cells (data not shown; sorting of CD90^+^ cells was recently reported in ref. [@R17]). An equal percentage of CD57^+^ and CD107b^+^ cancer cells was found.

In 8 of 10 laser-captured stromal cell sample pairs, an increase in CD90 transcript level in cancer was obtained by qRT-PCR analysis using primers to the 3′ UTR ([Fig. 3](#F3){ref-type="fig"}). The estimated fold increase in cancer over non-cancer ranged from 1.2 to 7.6. There was no increase detected in 2 cases. This increase in CD90 transcript corresponded with the increase in CD90 protein detected in tumor tissue samples.

Detection of CD90 protein in urine {#S14}
----------------------------------

Since CD90 might be released from cells, voided urine from cancer patients might contain detectable amounts of CD90. To assess whether CD90 could be a viable prostate cancer biomarker, urine was collected from patients and healthy donors, and analyzed by proteomics methods. The collected patient urine samples were first shown by Western blot analysis to contain such prostate-abundant proteins as ACPP and AZGP1 (data not shown). The major urinary proteins identified through in-gel digestion included uromodulin, MAC-2 binding protein, albumin, immunoglobulin γ1, VIP-36, AMBP, APOD, prothrombin, immunoglobulin κ, prostaglandin-h2-isomerase ([Fig. 4](#F4){ref-type="fig"}). Proteomic analysis of urine samples from prostate cancer patients (n=3, labeled with d9) identified a CD90 proteotypic peptide, VTSLTAC\*LVDQSLR (C\* to indicate ICAT-labeled Cys residue), in the pre-op samples but not in the post-op samples (labeled with d0, [Fig. 5](#F5){ref-type="fig"}). At the same time, a drop in PSA (as represented by peptide KLQC\*VDLHVISNDVC\*AQVHPQK) following surgical removal of the gland was seen in the post-op urine. The ICAT method did not specifically target secreted proteins; the relative fractions of the identified proteins (n=285) was: 28% secreted, 10% extracellular, 25% transmembrane, 24% intracellular, and 13% unknown. PSP~94~/MSMB, a Cys-rich prostate secretory protein, showed the highest d9/d0 ratio at \>10.

Analyzed by a different method, a CD90 peptide, WVGGPCAAGP, detected in a pre-op urine ([Fig. 6](#F6){ref-type="fig"}) matched the *N*-terminus of a variant CD90 protein (NCBI accession number BAD92446) encoded by a cDNA clone found in a human library. This variant differs from the T-cell CD90 at both the *N*- and *C*-termini. The two CD90 proteins appear to arise from differential splicing ([Fig. 7](#F7){ref-type="fig"}). In the same analysis, a peptide for the BCMP11 protein was also detected ([Fig. 6](#F6){ref-type="fig"}). BCMP11 (breast cancer membrane protein 11, also known as AGR3) was one of the genes encoding secreted/extracellular proteins found up-regulated in CD26^+^ prostate cancer cells compared to CD26^+^ luminal cells.[@R18]

Discussion {#S15}
==========

CD90 was first identified in the thymus as a T-cell maturation and differentiation marker (<http://www.ncbi.nlm.nih.gov/prow/>). Although known to be expressed in primitive hematopoietic progenitor cells, thymocytes and fibroblasts, CD90 has an unknown role in prostate biology. Studies have reported differential expression of CD90 in fibroblasts from many tissues including lung, myometrium, and orbit.[@R19] CD90 expression distinguishes fibroblasts by several functional properties: a) their differentiation potential -- CD90^+^ myofibroblastic *vs.* CD90^−^ lipofibroblastic;[@R20] b) their responsiveness to growth factor signaling -- CD90^−^ fibroblasts respond to PDGF, IL-1β, IL-4 with increased TGF-β activity, Smad3 phosphorylation, expression of α smooth muscle actin and fibronectin; whereas CD90^+^ fibroblasts resist stimulation by these factors.[@R21] In addition, fibroblast activation of CD90 expression is dependent upon participation of the CD40-ligand pathway and TGF-β signaling.[@R22],[@R23] It is possible that CD90^+^ prostate stromal fibroblastic cells might also behave differently compared to non-cancer-associated CD90^lo^ stromal cells.

In prostate cancer, there could be defects in stromal/epithelial interaction. The stroma is populated predominantly by smooth muscle cells \[which are desmin^+^, caldesmon^+^, α-smooth muscle actin (αSMA)^+^\] with few myofibroblasts (αSMA^+^, vimentin^+^) and fibroblasts (vimentin^+^). In cancer, the proportion of smooth muscle cells is decreased while the amount of collagen fibers is increased.[@R17],[@R24],[@R25] There is also loss of androgen receptor[@R26] and calponin[@R27] expression. Does the emergence of CD90^+^ cells represent a shift in stromal cell differentiation? The stromal cells are characterized as CD49a^+^, CD56^+^, and CD90^lo^ in benign tissue.[@R28] When prostate stromal cells are cultured in vitro, the resultant population of cells was found by flow cytometry to have increased representation of CD90^+^ cells and decreased representation of CD56^+^ cells.[@R29] Transcriptomes of CD90^+^ cells sorted from tumor specimens have recently been reported by us,[@R17] which showed cancer-associated stromal cells had lower expression of smooth muscle cell genes. In other cancers, the fibroblasts of melanoma also stain strongly for CD90.[@R30]

Quantitative proteomic analysis of tissue samples found increased CD90 glycopeptide in cancer *vs.* non-cancer. Proteins with increased cancer expression were a minority, perhaps reflecting the fact that tumor cells are non-functional cell types. TIMP1 is an example of a highly expressed secreted proteins showing cancer non-expression, which we have reported previously.[@R6] The presence of CD90 in the media could be due to cell shedding, secretion, or enzymatic release. Because of its elevated expression, CD90 appears to be a good cancer biomarker candidate, especially given the fact that not many candidates with increased expression specific to cancer cells have been detected in these proteome profiling experiments. Other prostate cancer up-regulated genes like AMACR (α-methylacyl-CoA racemase) is localized to peroxisomes and mitochondria, HPN (hepsin) is a single-pass type II membrane serine protease, PCA3 (prostate cancer antigen) is a non-protein coding transcript. Because extracellular CD90 could be found in tissue collagenase digestion supernatant we wondered whether CD90 might be detected in the urine of cancer patients. A urine test would represent a desirable non-invasive means of cancer detection. Accordingly, a CD90 proteotypic peptide was found to be of higher abundance in urine samples from 3 patients compared to urine samples of post-op (and healthy) men. Though we anticipate investigating correlation of CD90 expression with clinical outcome, such an investigation is a project planned for the time when we have enough cases for statistical analysis, along with IRB approval to obtain outcomes data. However, since CD90 is overexpressed in virtually all tumors it may not have prognostic value like differentially expressed CD10.[@R4] One testable prediction is that urinary amount of CD90 could correlate to tumor size.

The detection of a variant CD90 in urine of a cancer patient suggests that cancer-associated stromal cells produce this variant. This variant was previously identified from a human protein-coding cDNA project (RIKEN), and there are no documented studies on the encoded protein. The variant encoding mRNA was not identified in a T-cell cDNA library from which CD90 was first cloned.[@R31] Thus, it is possible that stromal fibromuscular cells and lymphocytes express different CD90 protein. The variant (stromal) version does not contain a hydrophobic transmembrane segment at its *C*-terminus. An initiating Met codon has not been identified for this variant. The *N*-terminal WVGGPCAAGP sequence is also found at position 213-222 of the chimpanzee (*Pan troglodytes*) Thy-1 protein (XP_508814) inferred from a cloned cDNA sequence. The predicted leader PGPSLHF of the human BAD92446 sequence preceding the tryptic cleavage site (Arg) is not found in the chimpanzee sequence, which has an in-frame Met codon 210 amino acids upstream. The chimpanzee Thy-1 *C*-terminus is the Leu-rich version of the human AAA61180 sequence. Thus, more research is needed to characterize this human variant CD90 protein. The existence of a CD90 variant would enhance the value of CD90 as a biomarker because it can be distinguished from the CD90 synthesized by white blood cells. In the PeptideAtlas database (<http://www.peptideatlas.org/>), this variant CD90 peptide was not scored in large-scale mass spectrometry analysis of healthy human plasma. A follow-up study is being designed to examine the clinical utility of a CD90 urine test. Monoclonal antibodies need to be developed that can recognize specifically this CD90 variant.

In summary, we have identified a stromal cell type (CD90^+^ fibroblasts) and a molecule (CD90) that distinguishes cancer-associated stroma from "benign" stroma in the prostate. CD90 can be used to isolate cancer-associated stromal cells by flow or magnetic bead sorting, or immunofluorescence-directed laser microdissection to begin to understand mechanisms by which the stroma affects growth and progression of prostate cancer. In addition, CD90 might serve as a molecular target for therapy to regulate the growth of primary prostate cancer and as a diagnostic tool for atypical foci of prostate glands that are challenging to diagnose definitively using currently available histologic tools. We are beginning to collect these specimens in the frozen format because we are limited by the absence of an anti-CD90 antibody that works in sections of formalin-fixed, paraffin embedded tissue. Since all our studies were conducted on frozen sections of clearly diagnosable prostate cancer, the histology of most of the samples is of insufficient quality to identify "atypical glands".
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![CD90 glycoprotein in cancer tissue. Western blot analysis of tissue digestion media detected a diffuse CD90 band at ∼27 kDa, which is larger than the calculated molecular weight of CD90 (∼16 kDa) based on the amino acid sequence. Cancer is characterized as CD90^hi^ and non-cancer as CD90^lo^. Both peripheral zone and transition zone cancer show increased CD90 expression compared to non-cancer. Expression level does not appear to vary with Gleason scores. Note that the Gleason score applies to the case not necessarily to the specimens obtained for collagenase digestion. The 30-kDa TIMP1 can be used to characterize non-cancer specimens since TIMP1 is synthesized by luminal cells and not cancer cells.](nihms203764f1){#F1}

###### 

CD90 staining of cancer-associated stromal cells. A. CD90 staining of tissue specimen 99-068D shows increased reactivity localized to the tumor foci. Staining in non-cancer is restricted to a cell layer adjacent to the basal epithelium. Blood vessels are also positive for CD90. Original magnifications are indicated in the individual photomicrographs. B. The transition zone cancer, 04-023, contained both tissue without benign glands (top panels) and cancer-rich tissue with scattered benign glands (bottom left). The tumor cells in 04-023C are stained by CD26 (top left). 01-180C contained a large tumor focus with crowded glands. Original magnification 40×.
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![CD90 expression analysis in laser-captured stromal cells. Matched cancer and non-cancer specimens were prepared from cases listed on the *x*-axis. The fold differences in CD90 transcript expression for the laser-captured stromal cell samples are indicated on the *y*-axis in the range of 0.1- to 10-fold cancer over non-cancer. Increased transcript was seen in 8 of 10 cancer-associated stromal cell samples.](nihms203764f3){#F3}

![Major human urinary proteins. Polyacrylamide gel-resolved urinary proteins from 4 healthy donor specimens are shown. Identification was achieved by in-gel digestion and mass spectrometry. The band intensities show that there is no significant variation between samples.](nihms203764f4){#F4}

![CD90 in urine. Single ion traces of the mass from heavy (d9, pre-op urine) and light (d0, post-op urine) ICAT-labeled peptides indicate that PSA and CD90 are detectable in prostate cancer patient urine. The elution profiles (single ion traces of the peptide mass over time) of heavy labeled peptide masses and those of the corresponding light labeled peptide masses are highlighted. The detected peptide sequences are shown below the traces. The weight difference of 18 in PSA is due to the two labeled Cys residues. Both PSA (more abundant than CD90, *y*-axis) and CD90 show a similar trend wherein both proteins are present in the pre-op sample but below detection limit in the post-op sample.](nihms203764f5){#F5}

![CD90 variant. The panel shows LC-SRM-MS detection of 7 MS/MS fragments of a peptide specific to the CD90 variant protein (BAD92446) encoded by a CD90 cDNA clone (AB209209) in a pre-op urine sample. In the same sample, a peptide of the cancer upregulated BCMP11 was also detected.](nihms203764f6){#F6}

![CD90 gene structure. The top panel shows the amino acid sequence difference (in red) between the T-cell CD90 (AAA61180) and CD90 variant (BAD92446). In the AAA61180 sequence, MNLAISIALLLTVLQVSR constitutes the signal sequence. The bottom panel shows the gene arrangements of these two CD90 coding regions: nucleotides in red are for the T-cell CD90, and nucleotides in green are for variant CD90; common coding sequence is in blue. The start codon of AAA61180 and the stop codons of the two coding regions are underlined. A stop codon (TAG) precedes the CD90 variant coding sequence. Sequences of the CD90 primers in RT-PCR analysis are highlighted in gray.](nihms203764f7){#F7}

###### 

Cancer *vs*. non-cancer *N*-glycoproteomes. The ratio is the relative abundance of the detected isotopic peptides in cancer compared to non-cancer. The results from two pairs of samples (\#1 and \#2) are shown. Data entry for CD90 is highlighted.

  protein       \# 1 ratio   \# 2 ratio   annotation
  ------------- ------------ ------------ ----------------------------------------------------------------------
  IPI00024284   0.19         0.61         basement membrane-specific heparan sulfate proteoglycan core protein
  IPI00289983   0.22         0.06         prostate acid phosphatase
  IPI00178017   0.24         0.54         angiotensin I converting enzyme isoform 3
  IPI00022792   0.36         0.78         microfibril-associated glycoprotein 4
  IPI00023673   0.38         0.81         MAC-2 binding protein
  IPI00383517   0.8          0.49         prostate specific antigen
  IPI00298281   1.39         1.87         laminin γ-1 chain
  IPI00329573   1.94         1.36         long splice isoform of Q99715 collagenα 1 (XII) chain
  IPI00022892   5.04         4.49         CD90, Thy-1 membrane glycoprotein
  IPI00328113   7.18         1.6          fibrillin 1

[^1]: Present addresses: HZ: Department of Pathology, Johns Hopkins University, Baltimore, Maryland, USA; MY: Division of Biotechnology, Dalian Institute of Chemical Physics, Chinese Academy of Sciences, Dalian, China; PDvH: Proteomics Resources, University of Washington, Seattle, Washington, USA; LWT: XORI Corp., Seattle, Washington, USA
